Overview

Safety and Pharmacokinetic Study of BIO 300 Capsules

Status:
Completed
Trial end date:
2007-10-01
Target enrollment:
Participant gender:
Summary
This trial is designed to evaluate the safety and pharmacokinetics of BIO 300 capsules when administered orally to healthy male and female volunteers. BIO 300 is expected to be safe for use starting at 500 mg.
Phase:
Phase 1
Details
Lead Sponsor:
Humanetics Corporation
Collaborator:
United States Department of Defense